'Line therapy' presentation slideshows

Optimizing Treatment for HER2-Positive Advanced Breast Cancer

Optimizing Treatment for HER2-Positive Advanced Breast Cancer. Program Goals. CLEOPATRA Study Design. First-Line Therapy of HER2+ MBC. Therapy of MBC After Progression on First-Line Anti-HER2 Treatment. EMILIA: PFS. EMILIA: OS at Second Interim Analysis. EMILIA: Hematologic Adverse Events.

1.59k views • 52 slides

Updates in the Management of ITP

791 views • 40 slides

New Perspectives on Second-Line Therapy for NSCLC

New Perspectives on Second-Line Therapy for NSCLC. Tony Mok, MD (Moderator) Professor, Department of Clinical Oncology, Chinese University of Hong Kong; Honorary Consultant, Prince of Wales Hospital, Hong Kong, China. Overview.

635 views • 38 slides

Clinical prognostic factors

486 views • 32 slides

Management of Chronic Heart Failure

Management of Chronic Heart Failure. Dr A Al-Mohammad, MD, FRCP(Edin ), FRCP(Lond ) Consultant Cardiologist Sheffield Teaching Hospitals NHS Foundation Trust 22 nd March 2012. Conflicts of Interest. PI for Emphasis and STICH in Sheffield

485 views • 29 slides

353 views • 27 slides

375 views • 27 slides

Antibiotics

768 views • 23 slides

Palliative Chemotherapy in Epithelioid Sarcoma

407 views • 21 slides

Principles and Objectives

Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-Limited Settings: Towards Universal Access Recommendations for a public health approach 2006 revision. Principles and Objectives. Standardized formulary for 1 st and 2 nd line ART NNRTI-based for 1 st line

300 views • 20 slides

Consensus Statement on NHL - 2005

354 views • 20 slides

Viviane Dias Lima British Columbia Centre for Excellence in HIV/AIDS vlima@cfenet.ubc

British Columbia Centre for Excellence in HIV/AIDS. What can we learn from the impact of dramatically scaling-up treatment on future costs and prevention efforts?. Viviane Dias Lima British Columbia Centre for Excellence in HIV/AIDS vlima@cfenet.ubc.ca.

300 views • 20 slides

COIN Trial design

Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first line advanced colorectal cancer (aCRC): mature results of the MRC COIN trial

357 views • 18 slides

Rifabutin for TB for people on ART

Rifabutin for TB for people on ART. Reuben Granich WHO HIV/AIDS Department. HIV/TB Core Group Meeting Addis Ababa, Ethiopia, 11-12 November 2008. Towards Universal Treatment Access. Nearly one million more people on antiretroviral therapy 54% increase in one year in sub-Saharan Africa.

354 views • 17 slides

The ICCS MNE standardisation document

389 views • 15 slides

Rare Tumour Working Group

191 views • 11 slides

Lee M Ellis, MD Colorectal Cancer Update Think Tank Meeting June 24, 2005

FOLFOX4 with or without Bevacizumab in Previously Treated Advanced Colorectal Cancer: Results from ECOG-E3200. Lee M Ellis, MD Colorectal Cancer Update Think Tank Meeting June 24, 2005. VEGF Family and Receptors. PlGF VEGF-B. VEGF-A. VEGF-C, D. Bevacizumab T 1/2 ~20 days. X. X. X.

251 views • 10 slides

Thank you for downloading this update. Please feel free to use it for educational purposes.

International multicenter randomized phase III study of 1 st line erlotinib followed by 2 nd line cisplatin + gemcitabine vs. 1 st line cisplatin + gemcitabine followed by 2 nd line erlotinib in advanced NSCLC. The TORCH trial.

256 views • 8 slides

Reviewer: Dr. Ron Burkes Date posted: June 21, 2007

Phase III study of Gefitinib vs Docetaxel in Japanese Patients with NSCLC who Failed 1 or 2 Chemotherapy Regimens Author: Niho PASCO 25:#7509, 2007. Reviewer: Dr. Ron Burkes Date posted: June 21, 2007. Treatment A: Gefitinib 250 mg/day ? Post study treatment. R.

180 views • 7 slides

Conclusion

IS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION (ANATOLIAN SOCIETY OF MEDICAL ONCOLOGY )

132 views • 1 slides